Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1973 1
1974 1
1975 8
1976 9
1977 4
1978 8
1979 10
1980 12
1981 14
1982 20
1983 39
1984 42
1985 61
1986 60
1987 61
1988 79
1989 56
1990 78
1991 56
1992 65
1993 56
1994 69
1995 60
1996 59
1997 52
1998 53
1999 47
2000 46
2001 55
2002 41
2003 43
2004 42
2005 46
2006 45
2007 32
2008 37
2009 42
2010 32
2011 27
2012 32
2013 22
2014 29
2015 29
2016 34
2017 32
2018 24
2019 24
2020 26
2021 31
2022 23
2023 16
2024 18
2025 21
2026 7

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,846 results

Results by year

Filters applied: . Clear all
Page 1
Lutropin alfa.
Dhillon S, Keating GM. Dhillon S, et al. Drugs. 2008;68(11):1529-40. doi: 10.2165/00003495-200868110-00005. Drugs. 2008. PMID: 18627209 Review.
Dose-finding studies revealed a significant dose-dependent increase in the rate of optimal follicular development among women with hypogonadotropic hypogonadism and profound LH deficiency (<1.2 IU/L) who received subcutaneous lutropin alfa 0-225 IU/day plus follitrop …
Dose-finding studies revealed a significant dose-dependent increase in the rate of optimal follicular development among women with hypogonad …
Outcomes of new quality standards of follitropin alfa on ovarian stimulation: meta-analysis of previous studies.
Saz-Parkinson Z, López-Cuadrado T, Bouza C, Amate JM. Saz-Parkinson Z, et al. BioDrugs. 2009;23(1):37-42. doi: 10.2165/00063030-200923010-00004. BioDrugs. 2009. PMID: 19344190 Review.
Several clinical trials have tried to assess the clinical implications of the physicochemical improvements in the dosing of follitropin alfa filled by mass (FbM). The aim of this study was to perform a meta-analysis of previous studies in order to assess the efficac …
Several clinical trials have tried to assess the clinical implications of the physicochemical improvements in the dosing of follitropin …
Improving the consistency of ovarian stimulation: follitropin alfa filled-by-mass.
Wikland M, Hugues JN, Howles C. Wikland M, et al. Reprod Biomed Online. 2006 Jun;12(6):663-8. doi: 10.1016/s1472-6483(10)61078-4. Reprod Biomed Online. 2006. PMID: 16792840 Review.
New developments have led to the production of follitropin alfa filled by mass. This is a highly consistent FSH preparation improving the consistency of ovarian response and reducing the risk of cycle cancellation. ...
New developments have led to the production of follitropin alfa filled by mass. This is a highly consistent FSH preparation im …
Predictive factors and a corresponding treatment algorithm for controlled ovarian stimulation in patients treated with recombinant human follicle stimulating hormone (follitropin alfa) during assisted reproduction technology (ART) procedures. An analysis of 1378 patients.
Howles CM, Saunders H, Alam V, Engrand P; FSH Treatment Guidelines Clinical Panel. Howles CM, et al. Curr Med Res Opin. 2006 May;22(5):907-18. doi: 10.1185/030079906X104678. Curr Med Res Opin. 2006. PMID: 16709312
An analysis was undertaken with the objective of determining whether specific factors could optimally predict a response to stimulation in ART, and to then develop a corresponding treatment algorithm that could be used to calculate the optimal starting dose of recombinant human f …
An analysis was undertaken with the objective of determining whether specific factors could optimally predict a response to stimulation in A …
Assessment of the biopotency of follitropin alfa and lutropin alfa combined in one injection: a comparative trial in Sprague-Dawley rats.
Alper M, Meyer R, Dekkers C, Ezcurra D, Schertz J, Kelly E. Alper M, et al. Reprod Biol Endocrinol. 2008 Jul 22;6:31. doi: 10.1186/1477-7827-6-31. Reprod Biol Endocrinol. 2008. PMID: 18647398 Free PMC article.
RESULTS: FSH bioactivities were similar (p > 0.10) between the individual follitropin alfa RFF test solution (84.2 IU) and follitropin alfa RFF/lutropin alfa (87.6 IU) mixtures prepared within 1 h of injection and stored at 6 +/- 2 degrees C. …
RESULTS: FSH bioactivities were similar (p > 0.10) between the individual follitropin alfa RFF test solution (84.2 IU) and …
Lutropin alfa: new preparation. Combined with follitropin for follicular development: no better than menotropin.
[No authors listed] [No authors listed] Prescrire Int. 2003 Jun;12(65):91-2. Prescrire Int. 2003. PMID: 12825571
(1) The reference ovarian stimulant for women with severe FSH and LH deficiency and pituitary dysfunction is menotropin (postmenopausal urinary human gonadotrophin (hMG)). (2) A recombinant LH, lutropin alfa, has now been licensed for this use, in combination with recombin …
(1) The reference ovarian stimulant for women with severe FSH and LH deficiency and pituitary dysfunction is menotropin (postmenopausal urin …
Patient evaluation of the use of follitropin alfa in a prefilled ready-to-use injection pen in assisted reproductive technology: an observational study.
Welcker JT, Nawroth F, Bilger W. Welcker JT, et al. Reprod Biol Endocrinol. 2010 Sep 15;8:111. doi: 10.1186/1477-7827-8-111. Reprod Biol Endocrinol. 2010. PMID: 20843323 Free PMC article.
Approximately one third of respondents rated the prefilled follitropin alfa pen as easier to use than the follitropin beta pen with reloadable cartridges. The majority (3378/4024, 83.9%) of patients had a general preference for the prefilled follitropin …
Approximately one third of respondents rated the prefilled follitropin alfa pen as easier to use than the follitropin b …
A large, multicentre, observational, post-marketing surveillance study of the 2:1 formulation of follitropin alfa and lutropin alfa in routine clinical practice for assisted reproductive technology.
Bühler K, Naether OG, Bilger W. Bühler K, et al. Reprod Biol Endocrinol. 2014 Jan 14;12:6. doi: 10.1186/1477-7827-12-6. Reprod Biol Endocrinol. 2014. PMID: 24423045 Free PMC article.
Primary endpoint: reason for prescribing the 2:1 formulation of follitropin alfa and lutropin alfa. Secondary variables included: COS duration/dose; oocytes retrieved; fertilization; clinical pregnancy; ovarian hyperstimulation syndrome (OHSS). ...CONCLUSIONS …
Primary endpoint: reason for prescribing the 2:1 formulation of follitropin alfa and lutropin alfa. Secondary variables …
Stimulation of spermatogenesis with recombinant human follicle-stimulating hormone (follitropin alfa; GONAL-f): long-term treatment in azoospermic men with hypogonadotropic hypogonadism.
Matsumoto AM, Snyder PJ, Bhasin S, Martin K, Weber T, Winters S, Spratt D, Brentzel J, O'Dea L. Matsumoto AM, et al. Fertil Steril. 2009 Sep;92(3):979-990. doi: 10.1016/j.fertnstert.2008.07.1742. Epub 2008 Oct 18. Fertil Steril. 2009. PMID: 18930190 Free article. Clinical Trial.
OBJECTIVE: To demonstrate the efficacy and safety of follitropin alfa administered with hCG on spermatogenesis in adult male hypogonadotropic hypogonadism (HH) patients. ...RESULT(S): In total, 22 of 29 patients (75.9%) who received > or =1 dose of follitropin …
OBJECTIVE: To demonstrate the efficacy and safety of follitropin alfa administered with hCG on spermatogenesis in adult male h …
1,846 results